Drugs For Osteoarthritis Pain Market Size, Share, Growth, and Industry Analysis, By Type (NSAIDs, Opioids, Viscosupplements, Corticosteroids, Others), By Application (Hospital, Clinics, Household), Regional Insights and Forecast to 2035

Drugs For Osteoarthritis Pain Market Overview

The global Drugs For Osteoarthritis Pain Market size estimated at USD 13577.29 million in 2026 and is projected to reach USD 30495.68 million by 2035, growing at a CAGR of 9.41% from 2026 to 2035.

The Drugs For Osteoarthritis Pain Market continues to expand due to the increasing prevalence of osteoarthritis among aging populations and obese patients worldwide. More than 595 million people were living with osteoarthritis globally in 2023, with knee osteoarthritis accounting for nearly 60% of diagnosed cases. Around 73% of patients affected are older than 55 years, while women represent approximately 60% of total diagnosed cases. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most prescribed treatment category, contributing nearly 48% of prescriptions for osteoarthritis pain management. Injectable therapies, including corticosteroids and viscosupplements, account for approximately 27% of therapeutic interventions, while topical pain medications represent nearly 18% of treatment utilization across outpatient settings.

The United States remains the largest individual market for drugs used in osteoarthritis pain treatment. More than 32.5 million adults in the country are diagnosed with osteoarthritis, with knee osteoarthritis affecting approximately 14 million individuals. Nearly 43% of patients receive prescription NSAIDs during treatment, while about 29% undergo corticosteroid injections annually. Approximately 6 million patients receive viscosupplement therapy each year. Adults aged 65 years and older represent nearly 57% of prescription demand. Hospital-based treatment accounts for approximately 38% of prescription volume, while specialty clinics contribute nearly 44%, reflecting strong demand for advanced pharmacological pain management across the United States.

Key Findings

• Key Market Driver: Rising osteoarthritis prevalence increased treatment demand by 62%.
• Major Market Restraint: Long-term NSAID safety concerns affected 41% of patients.
• Emerging Trends: Biologic therapy research increased by 46%.
• Regional Leadership: North America led with 39% of global market demand.
• Competitive Landscape: Leading manufacturers controlled 54% of the market.
• Market Segmentation: NSAIDs held the largest share at 48%.
• Recent Development: Clinical-stage drug development increased by 36%.

Drugs For Osteoarthritis Pain Market Latest Trends

The Drugs For Osteoarthritis Pain Market is experiencing rapid transformation through improved drug formulations, greater use of targeted therapies, and increasing preference for safer long-term pain management solutions. NSAIDs continue to dominate prescribing practices, accounting for nearly 48% of pharmacological treatment, while topical NSAID utilization increased by 22% during the last two years because of lower systemic adverse effects. Corticosteroid injections remain widely used for acute symptom relief, representing approximately 19% of therapeutic procedures performed in orthopedic clinics.

Combination therapy has become increasingly common, with approximately 44% of moderate-to-severe osteoarthritis patients receiving multiple pharmacological interventions. Digital health integration is improving medication adherence, increasing treatment compliance by nearly 18% among monitored patients. Personalized treatment selection based on disease severity, age, and comorbidity profiles is expanding across rheumatology and orthopedic practices. Hospital formularies have also increased availability of topical formulations, sustained-release corticosteroids, and non-opioid analgesics, supporting safer chronic pain management while reducing dependence on conventional opioid therapy.

Drugs For Osteoarthritis Pain Market Dynamics

DRIVER

" Rising demand for pharmaceuticals for chronic osteoarthritis pain management."

The primary growth driver for the Drugs For Osteoarthritis Pain Market is the increasing number of patients requiring long-term pharmacological treatment for chronic joint pain. Globally, more than 595 million individuals are living with osteoarthritis, and nearly 365 million suffer from knee osteoarthritis. Approximately 73% of patients are older than 55 years, creating continuous demand for prescription medications. NSAIDs remain the first-line therapy and account for nearly 48% of total treatment utilization. Around 43% of diagnosed patients receive prescription anti-inflammatory drugs during routine care, while corticosteroid injections are administered to nearly 29% of patients experiencing moderate or severe pain. Obesity has become another significant factor, with nearly 40% of osteoarthritis cases associated with excess body weight.

RESTRAINT

" Safety concerns associated with long-term drug therapy."

Long-term administration of osteoarthritis medications presents several safety concerns that limit treatment duration and prescribing frequency. Nearly 41% of chronic NSAID users experience gastrointestinal complications requiring monitoring or medication adjustment. Cardiovascular risk influences prescribing decisions for approximately 33% of patients with existing heart disease. Kidney-related adverse effects affect nearly 15% of elderly patients receiving prolonged NSAID therapy. Opioid medications represent only 11% of overall treatment use because prescribing restrictions have become significantly stricter following updated pain management guidelines. Approximately 26% of physicians prefer limiting repeated corticosteroid injections due to potential cartilage deterioration after frequent administration. Drug interactions are increasingly important because nearly 68% of osteoarthritis patients suffer from at least one additional chronic disease requiring multiple medications. These clinical limitations encourage physicians to balance pain relief with long-term safety, slowing adoption of certain pharmacological therapies despite increasing disease prevalence.

OPPORTUNITY

" Growth in innovative non-opioid and disease-modifying therapies."

Innovation represents one of the strongest opportunities within the Drugs For Osteoarthritis Pain Market. More than 180 clinical studies are currently investigating novel osteoarthritis therapies, while over 35 late-stage candidates are focused on improving pain relief and slowing disease progression. Non-opioid drug development programs account for nearly 62% of active pharmaceutical pipelines targeting osteoarthritis pain. Sustained-release injectable formulations have demonstrated improved patient compliance by reducing treatment frequency by approximately 30% compared with conventional injections. Topical drug formulations continue to expand, with prescription demand increasing by 22% in recent years due to improved safety profiles. Personalized medicine approaches supported by biomarkers and imaging technologies are expected to improve treatment selection accuracy.

CHALLENGE

" Limited availability of disease-modifying osteoarthritis drugs."

One of the greatest challenges facing the Drugs For Osteoarthritis Pain Market is the absence of widely approved disease-modifying therapies capable of reversing cartilage degeneration. Current medications primarily focus on symptom relief rather than structural joint repair. Nearly 70% of approved treatments are intended to reduce pain and inflammation without altering disease progression. Clinical trial failure rates remain high, with approximately 55% of investigational osteoarthritis drug candidates failing during advanced development because of insufficient clinical efficacy. More than 65% of patients eventually require treatment escalation after initial pharmacological therapy no longer provides adequate pain control. Regulatory requirements for demonstrating long-term joint preservation continue to increase development complexity, extending clinical evaluation periods beyond 5 years for many investigational therapies.

Drugs For Osteoarthritis Pain Market Segmentation

BY TYPE

NSAIDs: NSAIDs dominate the Drugs For Osteoarthritis Pain Market with an estimated 48% market share because they are recommended as the primary pharmacological treatment for mild and moderate osteoarthritis pain. More than 240 million NSAID prescriptions are issued annually across major healthcare systems for musculoskeletal disorders. Oral formulations remain the preferred option for nearly 68% of treated patients, while topical NSAIDs account for approximately 24% due to improved gastrointestinal safety. Clinical studies indicate pain reduction in nearly 70% of patients after regular NSAID therapy. Prescription demand is highest among adults aged 55 years and above, representing approximately 73% of users. Continuous product improvements, including extended-release formulations and topical gels, support sustained market leadership while reducing adverse effects associated with long-term systemic exposure.

Opioids: Opioids account for approximately 11% of the Drugs For Osteoarthritis Pain Market and are generally reserved for severe pain that does not respond adequately to first-line therapies. Regulatory guidelines have significantly reduced opioid prescribing over recent years, with prescription volumes declining by approximately 27% in several developed healthcare markets. Around 18% of patients with advanced osteoarthritis receive short-term opioid therapy before surgical intervention. Physicians increasingly favor limited treatment duration because prolonged opioid use is associated with dependency risks. Combination pain management strategies have reduced reliance on opioids, while enhanced monitoring programs have improved prescription oversight. Despite lower utilization, opioids remain clinically relevant for carefully selected patients experiencing severe pain.

Viscosupplements: Viscosupplements represent approximately 14% of the market and are primarily administered for knee osteoarthritis through intra-articular hyaluronic acid injections. More than 6 million viscosupplement injections are performed annually across developed healthcare systems. Approximately 65% of viscosupplement procedures are conducted in orthopedic specialty clinics, while hospitals account for nearly 25%. Patients with moderate osteoarthritis who are unsuitable for surgery represent the largest treatment population. Clinical evidence demonstrates symptom improvement lasting several months in a significant proportion of treated individuals. Product innovation has focused on single-injection formulations and higher molecular-weight hyaluronic acid preparations, improving patient convenience and treatment adherence.

Corticosteroids: Corticosteroids account for nearly 19% of treatment utilization and remain an important therapeutic option for rapid pain relief during inflammatory flare-ups. Around 29% of osteoarthritis patients receive at least one intra-articular corticosteroid injection annually. Hospital outpatient departments and orthopedic clinics together perform approximately 80% of these procedures. Sustained-release corticosteroid formulations have improved symptom control while reducing injection frequency. Clinical guidelines generally recommend limiting repeated injections because excessive use may accelerate cartilage deterioration. The growing availability of image-guided injection techniques has improved administration accuracy and patient outcomes, supporting continued demand for corticosteroid therapy.

Others: Other therapies contribute approximately 8% of the Drugs For Osteoarthritis Pain Market and include topical analgesics, capsaicin formulations, duloxetine, biologic investigational therapies, platelet-rich plasma adjunctive treatments, and emerging disease-modifying drug candidates. Topical analgesics account for nearly 45% of this category because of their favorable safety profile among elderly patients. More than 180 clinical studies continue evaluating innovative osteoarthritis therapies, while over 35 late-stage investigational drugs target pain reduction and structural disease modification. Pharmaceutical companies continue expanding research into regenerative medicine and precision pharmacology, creating future opportunities within this segment.

BY APPLICATION

Hospital: Hospitals account for approximately 38% of the Drugs For Osteoarthritis Pain Market, serving patients requiring comprehensive diagnosis, injectable therapies, and multidisciplinary pain management. Nearly 29% of corticosteroid injections and a substantial proportion of viscosupplement procedures are performed in hospital outpatient departments. Advanced imaging facilities improve diagnostic accuracy, enabling personalized treatment planning. Patients with severe osteoarthritis, multiple chronic diseases, or pre-surgical requirements frequently receive hospital-based pharmaceutical management. Increasing adoption of standardized clinical protocols has improved treatment consistency and patient monitoring.

Clinics: Clinics represent the largest application segment with approximately 44% market share. Orthopedic, rheumatology, and pain management clinics prescribe the majority of NSAIDs, topical medications, and injectable therapies. Nearly 65% of viscosupplement procedures occur within specialty clinics because they provide convenient outpatient services and shorter waiting times. Clinics also play a central role in follow-up care, medication adjustment, and long-term symptom monitoring. The growing number of musculoskeletal specialty centers has strengthened accessibility to osteoarthritis treatment, supporting continued expansion of this segment.

Household: Household treatment accounts for approximately 18% of the market and primarily includes self-administered oral NSAIDs, topical analgesics, and physician-prescribed maintenance medications. More than 70% of patients with mild osteoarthritis manage symptoms at home using prescribed pharmacological therapies combined with exercise and lifestyle modifications. Topical products have experienced increased adoption because they reduce systemic adverse effects while providing localized pain relief. Digital health applications and medication reminder systems have improved adherence among home-treated patients, supporting effective long-term disease management.Drugs For Osteoarthritis Pain Market Regional Outlook

Drugs For Osteoarthritis Pain Market Regional Outlook

North America

North America holds the largest share of the Drugs For Osteoarthritis Pain Market with approximately 39% of global demand. The United States accounts for the majority of regional consumption, with more than 32.5 million adults diagnosed with osteoarthritis. Nearly 14 million individuals suffer from knee osteoarthritis, while adults aged 65 years and older represent approximately 57% of treatment demand. NSAIDs account for nearly 47% of prescribed pharmacological therapies in the region, followed by corticosteroid injections at approximately 20%.

Europe

Europe accounts for approximately 29% of the global Drugs For Osteoarthritis Pain Market. More than 100 million people across European countries experience osteoarthritis symptoms, with knee and hip joints representing the most commonly affected anatomical sites. Individuals older than 60 years account for nearly 68% of diagnosed cases. NSAIDs remain the leading treatment category, representing approximately 46% of prescriptions, while corticosteroid injections account for around 18% of clinical interventions.

Topical formulations continue gaining popularity because they reduce systemic adverse effects, particularly among elderly patients with multiple chronic conditions. Universal healthcare systems improve patient access to prescription medicines, physiotherapy, and specialist consultations. Pharmaceutical manufacturers continue investing in sustained-release formulations and innovative pain management solutions. Clinical guideline adherence remains high throughout the region, supporting standardized treatment practices and improved long-term patient outcomes. Ongoing research collaborations between universities and pharmaceutical companies continue expanding therapeutic innovation.

Asia-Pacific

Asia-Pacific represents approximately 24% of the global Drugs For Osteoarthritis Pain Market and remains the fastest-expanding regional treatment landscape because of population aging and increasing diagnosis rates. More than 300 million individuals across the region experience osteoarthritis symptoms, with prevalence increasing significantly among adults older than 55 years. Countries including China, Japan, India, South Korea, and Australia continue expanding orthopedic care infrastructure and pharmaceutical accessibility.

Middle East & Africa

The Middle East & Africa account for approximately 8% of the global Drugs For Osteoarthritis Pain Market. The region continues demonstrating gradual growth due to expanding healthcare infrastructure, increasing life expectancy, and improved access to orthopedic services. Adults older than 60 years represent approximately 54% of diagnosed osteoarthritis patients. NSAIDs contribute nearly 52% of prescription demand, while corticosteroid injections account for around 16% of advanced pain management procedures.

Major urban hospitals increasingly provide viscosupplement therapy and image-guided injection techniques, improving treatment quality. Government investment in healthcare modernization has increased pharmaceutical availability in several Gulf countries and South Africa. Public awareness campaigns promoting early diagnosis and lifestyle modification have improved patient engagement. International pharmaceutical companies continue strengthening regional distribution networks, while local manufacturers increase production of generic medications, improving affordability and treatment accessibility across developing healthcare systems.

List of Top Drugs For Osteoarthritis Pain Companies

• Abbott Laboratories
• Johnson & Johnson
• Novartis International
• Pfizer
• AbbVie
• Abiogen Pharma
• Afferent Pharmaceuticals
• Astellas Pharma
• BioDelivery Sciences International
• CrystalGenomics
• Cytori Therapeutics
• Daiichi Sankyo
• Eli Lilly
• Endo Pharmaceuticals Holdings
• Horizon Pharma
• ICeutica
• Iroko Pharmaceuticals
• Merck
• Nuvo Research
• Regeneron Pharmaceuticals
• Sanofi
• SantoSolve
• Techfields Pharma
• Winston Pharmaceuticals
• Yooyoung Pharmaceutical
• Zynerba Pharmaceuticals

Top Two Companies Market Share

• Pfizer – Holds an estimated 11% share of the global Drugs For Osteoarthritis Pain Market
• AbbVie – Accounts for approximately 9% of the global market

Investment Analysis and Opportunities

Investment activity in the Drugs For Osteoarthritis Pain Market continues to increase as pharmaceutical companies prioritize non-opioid analgesics, disease-modifying osteoarthritis drugs (DMOADs), biologics, and sustained-release injectable formulations. More than 180 active clinical studies are investigating new osteoarthritis therapies, while over 35 candidates remain in late-stage clinical development. Research investment has increasingly shifted toward regenerative medicine, targeted anti-inflammatory therapies, and drug repurposing because no approved DMOAD currently exists.

Pharmaceutical manufacturers are expanding partnerships with biotechnology companies to accelerate clinical development and regulatory approvals. Approximately 62% of investigational programs emphasize non-opioid pain management to address long-term safety concerns associated with opioid therapy. Digital health technologies supporting medication adherence and patient monitoring are also receiving increased investment, improving treatment compliance by nearly 18% in monitored populations. Emerging healthcare markets continue presenting attractive expansion opportunities due to increasing osteoarthritis prevalence, growing elderly populations, and improved healthcare infrastructure. Local manufacturing of generic NSAIDs and topical formulations has strengthened product accessibility across developing countries. Investment opportunities also exist in precision medicine, biomarker-guided treatment selection, AI-assisted drug discovery, and advanced intra-articular delivery systems capable of extending therapeutic duration while reducing administration frequency. These factors continue attracting strategic collaborations between pharmaceutical companies, biotechnology firms, and clinical research organizations.

New Product Development

Product development within the Drugs For Osteoarthritis Pain Market is focused on improving efficacy, extending pain relief duration, and minimizing systemic adverse effects. More than 35 investigational therapies are currently progressing through advanced clinical development, targeting inflammatory pathways, cartilage preservation, and improved pain control. Drug developers are prioritizing non-opioid compounds because opioid utilization has declined significantly under updated prescribing guidelines.

Research into disease-modifying therapies has intensified through development of biologics, regenerative medicines, cartilage-protective agents, and repurposed pharmaceutical compounds. Artificial intelligence is increasingly used during early-stage compound screening and biomarker identification, accelerating candidate selection. Personalized medicine approaches based on imaging findings and patient-specific disease characteristics are expected to improve therapeutic outcomes. Pharmaceutical companies are also developing combination therapies integrating anti-inflammatory drugs with cartilage-supportive treatments to improve long-term disease management while reducing dependence on repeated injections and conventional oral medications.

Five Recent Developments (2023-2025)

• 2023: Positive Phase II clinical results for resiniferatoxin (RTX) demonstrated durable pain reduction for knee osteoarthritis, with efficacy maintained beyond 26 weeks at selected dose levels.
• 2024: A long-acting intra-articular corticosteroid formulation (EP-104IAR) demonstrated clinically meaningful pain relief lasting up to 24 weeks in a study involving 318 patients with knee osteoarthritis.
• 2024: Large clinical evidence supported the use of semaglutide in obese patients with knee osteoarthritis, reporting substantial reductions in pain scores over 68 weeks while achieving significant weight reduction.
• 2025: Multiple pharmaceutical companies expanded clinical research into disease-modifying osteoarthritis drugs, with more than 180 authorized-drug repurposing studies reviewed to identify new therapeutic opportunities.
• 2025: Several investigational DMOAD programs advanced through Phase II and Phase III development, reflecting continued industry focus on therapies capable of modifying disease progression rather than providing symptom relief alone.

Report Coverage of Drugs For Osteoarthritis Pain Market

The Drugs For Osteoarthritis Pain Market report provides comprehensive analysis of global pharmaceutical trends, therapeutic categories, prescribing patterns, technological innovations, competitive developments, and regional demand. The report evaluates more than 5 major drug categories, including NSAIDs, opioids, viscosupplements, corticosteroids, and emerging therapeutic approaches. It also examines 3 major application segments comprising hospitals, clinics, and household treatment settings.

The report includes assessment of patient demographics, disease prevalence, pharmaceutical innovation, regulatory developments, clinical trial activity, and healthcare infrastructure across North America, Europe, Asia-Pacific, and the Middle East & Africa. More than 180 ongoing clinical studies and over 35 advanced-stage investigational therapies are reflected within the innovation landscape to illustrate future treatment direction.

In addition, the report analyzes competitive positioning of leading pharmaceutical manufacturers, product development strategies, investment opportunities, emerging technologies, and recent industry developments occurring between 2023 and 2025. It also evaluates prescription trends, safety considerations, non-opioid treatment expansion, injectable therapy adoption, topical medication growth, and evolving clinical practice guidelines. The coverage supports strategic decision-making for pharmaceutical manufacturers, healthcare providers, investors, distributors, research organizations, and policy stakeholders seeking data-driven insights into the evolving global Drugs For Osteoarthritis Pain Market.